NCT00818168View on ClinicalTrials.gov

Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)

CompletedOBSERVATIONAL
Enrollment

320

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Spondylitis, Ankylosing
Interventions
BIOLOGICAL

Infliximab

"Dosage and infusion intervals were employed in~accordance to the Summary of Product Characteristics (SmPC)"

Sponsors

Collaborators (1)

Centocor, Inc.
All Listed Sponsors
collaborator

Centocor, Inc.

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00818168 - Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED) | Biotech Hunter | Biotech Hunter